Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma

M. Pedretti, C. Verpelli, J. Mårlind, G. Bertani, C. Sala, D. Neri, L. Bello

Research output: Contribution to journalArticle

Abstract

Background:Glioblastoma patients are still not cured by the treatments available at the moment. We investigated the therapeutic properties of temozolomide in combination with F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16, specific to the A1 domain of tenascin-C.Methods:We conducted three preclinical therapy studies, using subcutaneous and intracranial U87MG glioblastoma tumours xenografted in BALB/c nude mice. The same therapeutic schedule was used, consisting of five total administrations every third day, of 0.525 mg temozolomide, 20 g F16-IL2, the combination, or the control solution.Results: Immunohistochemical analysis of U87MG xenografts and of human glioblastoma specimens showed selective tumour staining of F16. A quantitative biodistribution confirmed the preferential tumour accumulation of radiolabelled F16-IL2. In the study with subcutaneous xenografts, the combination of F16-IL2 with temozolomide induced complete remission of the animals, which remained tumour free for over 160 days. The same treatment led to a consistent size reduction of intracranial xenografts and to a longer survival of animals. The immunocytokine promoted the recruitment of leukocytes into tumours of both models.Conclusion:The combined use of temozolomide with F16-IL2 deserves clinical investigations, which will be facilitated by the excellent safety profile in cynomolgus monkeys, and by the fact that F16-IL2 is in clinical trials in patients with cancer.

Original languageEnglish
Pages (from-to)827-836
Number of pages10
JournalBritish Journal of Cancer
Volume103
Issue number6
DOIs
Publication statusPublished - Sep 7 2010

Fingerprint

temozolomide
Glioblastoma
Interleukin-2
Heterografts
Neoplasms
Therapeutics
Tenascin
Macaca fascicularis
Nude Mice
Appointments and Schedules
Leukocytes

Keywords

  • A1 domain of tenascin-C
  • glioblastoma
  • immunocytokines
  • interleukin-2
  • temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. / Pedretti, M.; Verpelli, C.; Mårlind, J.; Bertani, G.; Sala, C.; Neri, D.; Bello, L.

In: British Journal of Cancer, Vol. 103, No. 6, 07.09.2010, p. 827-836.

Research output: Contribution to journalArticle

Pedretti, M, Verpelli, C, Mårlind, J, Bertani, G, Sala, C, Neri, D & Bello, L 2010, 'Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma', British Journal of Cancer, vol. 103, no. 6, pp. 827-836. https://doi.org/10.1038/sj.bjc.6605832
Pedretti, M. ; Verpelli, C. ; Mårlind, J. ; Bertani, G. ; Sala, C. ; Neri, D. ; Bello, L. / Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. In: British Journal of Cancer. 2010 ; Vol. 103, No. 6. pp. 827-836.
@article{a2ce84811a484298be57ea31e40401fc,
title = "Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma",
abstract = "Background:Glioblastoma patients are still not cured by the treatments available at the moment. We investigated the therapeutic properties of temozolomide in combination with F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16, specific to the A1 domain of tenascin-C.Methods:We conducted three preclinical therapy studies, using subcutaneous and intracranial U87MG glioblastoma tumours xenografted in BALB/c nude mice. The same therapeutic schedule was used, consisting of five total administrations every third day, of 0.525 mg temozolomide, 20 g F16-IL2, the combination, or the control solution.Results: Immunohistochemical analysis of U87MG xenografts and of human glioblastoma specimens showed selective tumour staining of F16. A quantitative biodistribution confirmed the preferential tumour accumulation of radiolabelled F16-IL2. In the study with subcutaneous xenografts, the combination of F16-IL2 with temozolomide induced complete remission of the animals, which remained tumour free for over 160 days. The same treatment led to a consistent size reduction of intracranial xenografts and to a longer survival of animals. The immunocytokine promoted the recruitment of leukocytes into tumours of both models.Conclusion:The combined use of temozolomide with F16-IL2 deserves clinical investigations, which will be facilitated by the excellent safety profile in cynomolgus monkeys, and by the fact that F16-IL2 is in clinical trials in patients with cancer.",
keywords = "A1 domain of tenascin-C, glioblastoma, immunocytokines, interleukin-2, temozolomide",
author = "M. Pedretti and C. Verpelli and J. M{\aa}rlind and G. Bertani and C. Sala and D. Neri and L. Bello",
year = "2010",
month = "9",
day = "7",
doi = "10.1038/sj.bjc.6605832",
language = "English",
volume = "103",
pages = "827--836",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma

AU - Pedretti, M.

AU - Verpelli, C.

AU - Mårlind, J.

AU - Bertani, G.

AU - Sala, C.

AU - Neri, D.

AU - Bello, L.

PY - 2010/9/7

Y1 - 2010/9/7

N2 - Background:Glioblastoma patients are still not cured by the treatments available at the moment. We investigated the therapeutic properties of temozolomide in combination with F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16, specific to the A1 domain of tenascin-C.Methods:We conducted three preclinical therapy studies, using subcutaneous and intracranial U87MG glioblastoma tumours xenografted in BALB/c nude mice. The same therapeutic schedule was used, consisting of five total administrations every third day, of 0.525 mg temozolomide, 20 g F16-IL2, the combination, or the control solution.Results: Immunohistochemical analysis of U87MG xenografts and of human glioblastoma specimens showed selective tumour staining of F16. A quantitative biodistribution confirmed the preferential tumour accumulation of radiolabelled F16-IL2. In the study with subcutaneous xenografts, the combination of F16-IL2 with temozolomide induced complete remission of the animals, which remained tumour free for over 160 days. The same treatment led to a consistent size reduction of intracranial xenografts and to a longer survival of animals. The immunocytokine promoted the recruitment of leukocytes into tumours of both models.Conclusion:The combined use of temozolomide with F16-IL2 deserves clinical investigations, which will be facilitated by the excellent safety profile in cynomolgus monkeys, and by the fact that F16-IL2 is in clinical trials in patients with cancer.

AB - Background:Glioblastoma patients are still not cured by the treatments available at the moment. We investigated the therapeutic properties of temozolomide in combination with F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16, specific to the A1 domain of tenascin-C.Methods:We conducted three preclinical therapy studies, using subcutaneous and intracranial U87MG glioblastoma tumours xenografted in BALB/c nude mice. The same therapeutic schedule was used, consisting of five total administrations every third day, of 0.525 mg temozolomide, 20 g F16-IL2, the combination, or the control solution.Results: Immunohistochemical analysis of U87MG xenografts and of human glioblastoma specimens showed selective tumour staining of F16. A quantitative biodistribution confirmed the preferential tumour accumulation of radiolabelled F16-IL2. In the study with subcutaneous xenografts, the combination of F16-IL2 with temozolomide induced complete remission of the animals, which remained tumour free for over 160 days. The same treatment led to a consistent size reduction of intracranial xenografts and to a longer survival of animals. The immunocytokine promoted the recruitment of leukocytes into tumours of both models.Conclusion:The combined use of temozolomide with F16-IL2 deserves clinical investigations, which will be facilitated by the excellent safety profile in cynomolgus monkeys, and by the fact that F16-IL2 is in clinical trials in patients with cancer.

KW - A1 domain of tenascin-C

KW - glioblastoma

KW - immunocytokines

KW - interleukin-2

KW - temozolomide

UR - http://www.scopus.com/inward/record.url?scp=77956450051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956450051&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605832

DO - 10.1038/sj.bjc.6605832

M3 - Article

C2 - 20736949

AN - SCOPUS:77956450051

VL - 103

SP - 827

EP - 836

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -